Catheter ablation was found to be superior to optimal drug therapy for the primary treatment of atrial fibrillation (AFib) in the randomized CABANA trial presented May 10 at the Heart Rhythm Society’s annual scientific sessions in Boston. However, there was a caveat.

DUBLIN and BARCELONA, Spain - MARCH 19, 2018 - Medtronic plc (NYSE: MDT) today announced one-year results from the CRYO4PERSISTENT AF study of ablation with the Arctic Front Advance(TM) Cryoballoon to isolate the pulmonary veins in patients with symptomatic persistent atrial fibrillation (AF).

A new study from Cincinnati’s Children’s Hospital has found that the use of a wearable cardioverter defibrillator (WCD) is safe and effective for treating ventricular arrhythmias in pediatric patients at risk from sudden cardiac death.

Apple devices just keep getting smarter. New research presented at this year’s Heart Rhythm Society (HRS) conference in Chicago showed that when paired with an artificial intelligence-based algorithm, the watch can detect atrial fibrillation (AFib). 

The Heart Rhythm Society (HRS) recently announced the late-breaking clinical trials sessions for the upcoming Heart Rhythm scientific sessions.

iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, announced the recent publication of two documents in support of extended continuous ambulatory monitoring for arrhythmia detection.

Trial results on same-day discharge for elective implantable cardioverter-defibrillator procedures may reassure centers, but whether the approach lowers cost is anyone’s guess.

Five electrophysiologists joined Cardiovascular Business editorial advisor Matthew R. Reynolds, MD, SM, for a discussion about how they will deliver quality care to a growing number of atrial fibrillation patients even as the U.S. healthcare system turns its focus from volume to value.